TruAlt Bioenergy

Why is TruAlt Bioenergy Ltd falling/rising?

As of 14-Jun, TruAlt Bioenergy Ltd's stock is rising to 502.45, reflecting a short-term trend reversal despite underlying financial weaknesses and high promoter pledges that pose risks to its stability.

As of 14-Jun, TruAlt Bioenergy Ltd's stock price is rising, currently at 502.45, with a change of 3.3 (0.66%) upward. This increase follows a trend reversal, as the stock has gained after two consecutive days of decline. Additionally, the stock reached an intraday high of Rs 511.75, reflecting a 2.52% increase during the trading session.<BR><BR>Despite the positive movement today, the stock has underperformed its sector by 1.18%. Over the past month, TruAlt Bioenergy Ltd has shown a significant increase of 9.98%, contrasting with the Sensex's modest gain of 1.30%. Year-to-date, the stock has performed well, with a return of 24.29%, while the Sensex has declined by 11.37%.<BR><BR>However, there are concerns regarding the stock's long-term fundamentals, including a weak Return on Capital Employed (ROCE) of 0% and a high Debt to EBITDA ratio of 5.60 times, which indicates a low ability to service debt. Furthermore, the company's profits have fallen by 43% over the past year, and 36.85% of promoter shares are pledged, which could exert downward pressure on the stock in a falling market.<BR><BR>In summary, while the stock is currently rising due to a short-term trend reversal and positive month-to-date performance, underlying weaknesses in financial fundamentals and high promoter pledges present risks that could affect its stability moving forward.

Which are the latest news on TruAlt Bioenergy?

What does TruAlt Bioenergy do?

TruAlt Bioenergy Ltd is a small-cap company in the commodity chemicals industry, reporting net sales of 596 Cr and a net profit of 60 Cr for the quarter ending March 2026, with a market cap of INR 4,595 Cr. Key metrics include a P/E ratio of 46.00 and a debt-equity ratio of 1.01.

Overview: <BR>TruAlt Bioenergy Ltd operates in the commodity chemicals industry and is categorized as a small-cap company.<BR><BR>History: <BR>The incorporation year is not specified, and there are no status changes mentioned. The latest quarter for which sales and profit are reported is March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 596 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 60 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 4,595 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 46.00 <BR>Industry P/E: 42 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.01 <BR>Return on Equity: 5.29% <BR>Price to Book: 3.01 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: Not available. <BR>Email: Not available. <BR>Website: Not available.

How big is TruAlt Bioenergy?

As of 10th June, TruAlt Bioenergy Ltd has a market capitalization of 4,595.00 Cr, with recent net sales of 1,727.51 Cr and a net profit of 96.00 Cr. Shareholder's funds are 769.00 Cr, and total assets amount to 3,029.73 Cr.

As of 10th June, TruAlt Bioenergy Ltd has a market capitalization of 4,595.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, TruAlt Bioenergy reported Net Sales of 1,727.51 Cr and a Net Profit of 96.00 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 769.00 Cr and Total Assets of 3,029.73 Cr.

Who are the peers of the TruAlt Bioenergy?

TruAlt Bioenergy's peers include Tata Chemicals, India Glycols, Gujarat Alkalies, GHCL, Tanfac Inds., and others. Management risk varies from excellent at GHCL and Chemplast Sanmar to below average at Fischer Medical, with Tanfac Inds. showing the highest 1-year return at 20.05% and GHCL the lowest at -32.65%.

Peers: The peers of TruAlt Bioenergy are Tata Chemicals, India Glycols, Gujarat Alkalies, GHCL, Tanfac Inds., Grauer & Weil, Chemplast Sanmar, Fischer Medical, Thirumalai Chem., J.G.Chemicals.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL and Chemplast Sanmar, while Average management risk is found at Tata Chemicals, India Glycols, Gujarat Alkalies, Tanfac Inds., Grauer & Weil, Thirumalai Chem., and J.G.Chemicals, and the rest. Below Average management risk is noted at Fischer Medical. Growth is rated as Excellent for Fischer Medical, Good for Tanfac Inds. and J.G.Chemicals, while Below Average growth is seen at Tata Chemicals, India Glycols, Gujarat Alkalies, GHCL, Grauer & Weil, Chemplast Sanmar, Thirumalai Chem., and the rest. Average capital structure is present at Tata Chemicals, India Glycols, and Thirumalai Chem., while Excellent capital structure is noted for Gujarat Alkalies, GHCL, Tanfac Inds., Grauer & Weil, and J.G.Chemicals, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Tanfac Inds. at 20.05%, while the lowest is GHCL at -32.65%. TruAlt Bioenergy's 1-year return is not available for comparison. Additionally, the peers with negative six-month returns include GHCL, Fischer Medical, Thirumalai Chem., and Chemplast Sanmar.

Are TruAlt Bioenergy Ltd latest results good or bad?

TruAlt Bioenergy Ltd's latest results are concerning, showing a 46.39% decline in net profit and a 34.34% drop in revenue year-on-year, despite slight improvements in operating margins. While the stock reacted positively, the company faces significant challenges due to high debt and revenue volatility.

TruAlt Bioenergy Ltd's latest results indicate a challenging financial performance. For Q4 FY26, the company reported a net profit of ₹59.88 crore, which is a significant decline of 46.39% year-on-year. Revenue also fell sharply by 34.34% year-on-year to ₹595.52 crore, although it showed some recovery from a very low figure in the previous quarter.<BR><BR>While the operating margin improved slightly to 19.94%, this was overshadowed by the drop in net profit margin, which decreased to 10.23%. The company is grappling with high interest expenses and a substantial debt burden, which raises concerns about its financial stability.<BR><BR>Despite these negative indicators, the stock reacted positively to the results, gaining 3.45% on the day of the announcement, as investors seemed to focus on sequential improvements rather than the year-on-year declines. Over the past three months, the stock has performed well, rallying 21.04%, significantly outperforming the broader market.<BR><BR>Overall, while there are some signs of recovery in terms of operating margins and stock performance, the underlying financial metrics suggest that TruAlt Bioenergy is facing serious challenges, particularly with revenue volatility and high leverage. Therefore, the latest results can be viewed as concerning rather than good.

Should I buy, sell or hold TruAlt Bioenergy Ltd?

When is the next results date for TruAlt Bioenergy Ltd?

The next results date for TruAlt Bioenergy Ltd is 22 May 2026.

The next results date for TruAlt Bioenergy Ltd is scheduled for 22 May 2026.